GlassScriptPhysician profile
Mark K Longmuir
NPI 1326278912
$504.51
in general payments reported to CMS, 2019-2025
13 companies · $90.97 in 2025
The $90.97 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.17 · 2021: $80.24 · 2022: $83.34 · 2023: $154 · 2024: $82.64 · 2025: $90.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $327.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.30 | 2023 | |
| Novo Nordisk INC | $61.12 | 2022-2025 | Ozempic |
| Astellas Pharma US INC | $55.00 | 2021 | |
| Kerecis Limited | $52.58 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Exact Sciences Corporation | $47.08 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $32.13 | 2019-2022 | |
| Lilly USA, LLC | $27.87 | 2023-2024 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $26.37 | 2025 | Eliquis |
| Irhythm Technologies, INC. | $18.65 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.27 | 2024 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $14.90 | 2022 | |
| Glaxosmithkline, LLC. | $13.04 | 2021 | |
| Merck Sharp & Dohme LLC | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Longmuir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.